The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval

Conclusion Overall, the increased use of ruxolitinib appears to have come predominantly at the expense of thalidomide and ESAs, while not having a large effect on the first line utilization of hydroxyurea. Teaser The FDA approval of ruxolitinib for intermediate and high-risk myelofibrosis in 2011 changed the therapeutic landscape of the disease. We investigated the first-line treatment choices for MF patients in the pre- and post-ruxolitinib eras and found that the increased use of ruxolitinib has come at the expense of several agents, but has not significantly affected the utilization of hydroxyurea in the first-line setting.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research